27 January 2020 - - Chinese drugmaker China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) will be increasing its production of its entire Traditional Chinese Medicine product line, in response to recent Chinese government pronouncements signaling a large expansion of the role and use of TCMPs in the Chinese health care system, the company said.

The initial directive, promulgated by the State Council of the People's Republic of China, contained general priorities in medical and healthcare system reform.

This was followed by guidelines issued by the State Council together with the Central Committee of the Communist Party of China, which specifically called for all community health service centres and township clinics in the country to offer TCM services by 2022, including TCM-based solutions for the prevention and treatment of, and rehabilitation from, illness and disease.

The guidelines were later reinforced with an announcement by the State Council on October 26, 2019.

After reviewing the Chinese authorities' guidelines, which further directed that existing TCM hospitals should increase their service capacity, China SXT has begun instituting plans to take advantage of the opportunity presented through an immediate ramp up in production of its entire TCM line, including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements.

Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is a pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use.